Satellos Announces New Data Further Demonstrating Safety, Tolerability, and Functional Impact of SAT-3247 in First-in-Human Trial of Adults with Duchenne Muscular Dystrophy

Core Insights - Satellos Bioscience Inc. announced new data demonstrating the tolerability and initial efficacy of SAT-3247 in adults with Duchenne muscular dystrophy (DMD) at the World Muscle Society Congress [1][2] Clinical Study Results - SAT-3247 showed a 118.6% mean improvement in maximum grip strength in the dominant hand and a 97.9% mean improvement in the non-dominant hand over a 28-day period, indicating significant muscle strength enhancement [3] - Participants also exhibited a 5.8% mean improvement in predicted forced vital capacity, contrasting with the typical annual decline of about 5% in adults with DMD [4] Safety and Tolerability - The Phase 1a/b study reported no moderate or severe drug-related adverse events, and no dose-limiting toxicities were observed [4] Future Clinical Development - The five adult patients from the Phase 1b trial will enroll in an 11-month open-label follow-up study, which will also include additional males aged 16-25 years with DMD [5] - A Phase 2 randomized, double-blind, placebo-controlled study is planned to evaluate SAT-3247 in ambulatory children with DMD, focusing on safety, tolerability, and muscle force [6] Drug Mechanism and Design - SAT-3247 is designed to regenerate skeletal muscle lost in DMD by targeting AAK1, a protein that can replace the signal normally provided by dystrophin in muscle stem cells [9]